CN109385459A - A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity - Google Patents

A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity Download PDF

Info

Publication number
CN109385459A
CN109385459A CN201811213728.7A CN201811213728A CN109385459A CN 109385459 A CN109385459 A CN 109385459A CN 201811213728 A CN201811213728 A CN 201811213728A CN 109385459 A CN109385459 A CN 109385459A
Authority
CN
China
Prior art keywords
cell
group
dna polymerase
bar
archaeal dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811213728.7A
Other languages
Chinese (zh)
Inventor
崔昌浩
邓营营
王黎
李茗达
李姗姗
马昆
郭兆明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian University of Technology
Original Assignee
Dalian University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian University of Technology filed Critical Dalian University of Technology
Priority to CN201811213728.7A priority Critical patent/CN109385459A/en
Publication of CN109385459A publication Critical patent/CN109385459A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a kind of basic elements of cell division by inhibiting DNA polymerase activity to inhibit the method for cell Proliferation, belongs to Biochemistry and Molecular Biology technical field.The archaeal dna polymerase used in us is found in PDB lane database, setting parameter optimizes the structure of archaeal dna polymerase;Then look for the active site of archaeal dna polymerase;Prepare BAR structural formula and optimizes;The method of LibDock carries out molecular docking, can successively check the docking structure of each ligand, be ranked up according to scoring functions.Data of the invention, which are established, may interfere with archaeal dna polymerase biocatalysis synthetic DNA in tumour cell in the basic element of cell division to inhibit on the survival of tumour cell and the basis of proliferation.

Description

A kind of basic element of cell division is by inhibiting DNA polymerase activity to inhibit cell Proliferation Method
Technical field
The present invention relates to ucleosides basic element of cell division N6- Benzyladenosine (BAR) is to the anti-swollen of human lung carcinoma cell line Tumor effect, belongs to Biochemistry and Molecular Biology technical field.
Background technique
At present more and more the study found that the basic element of cell division not only adjusts the growth and development of plant simultaneously to zooblast Proliferation and growth also play a significant role.Research finds some nucleoside form ortho-Topolin of the basic element of cell division Riboside(oTR)、Kinetin riboside(KR)、N6-Benzyladenosine(BAR)、N6- Isopentenyladenosine (iPR) has very strong toxicity and apoptosis-promoting effect to cancer cell in vitro.When thin with these Cause after born of the same parents' mitogen processing cancer cell the cell cycle it is different degrees of be obstructed and (or) apoptosis, this depends primarily on different Susceptibility of the cell line to the different basic elements of cell division.Although natural CK and their analog to the effect of zooblast Through repeatedly being reported, but there is presently no the researchs to basic element of cell division apoptosis-promoting effect of a system.
Polymerase (polymerase) is also known as archaeal dna polymerase, be special biocatalysis synthesis DNA (DNA) and The general designation of the class of enzymes of ribonucleic acid (RNA).12 kinds of archaeal dna polymerases, including polymerase are at least had found in eukaryocyte α, β, γ, δ, ε, ζ, η, θ, ι, κ, λ and μ, they are repaired by the proofreading effect or DNA for participating in DNA polymerization reaction exonuclease Multiple process, plays an important role to the maintenance of DNA replication dna fidelity, directly affects the stability of cytogenetics, therefore DNA polymerize Enzyme plays a significant role in DNA synthesis process.DNA synthesis process is the important link in proliferation process, therefore DNA is poly- The activity of synthase may influence proliferation process.
Lung cancer is currently disease incidence and the highest malignant tumour of the death rate in global range.In the past 20 years, due to pushing greatly The disease incidence of row smoking cessation, western countries' male lung cancer such as Europe and the U.S. has been begun to decline, but the disease incidence of female lung cancer is held It is continuous to rise.China is that cigarette produces and sells big country, no matter male or women, the disease incidence of lung cancer is in that lasting rise becomes Gesture is risen faster with women disease incidence especially.Clinical research shows carcinoma in situ cure rate close to 5 years of 100%, I phase patients with lung cancer Survival rate is up to 60%~90%, and 5 years survival rates of III b and IV patient only 5%~20%.Clinically for treating the normal of lung cancer Although rule drug plays an important role to treatment, there is apparent toxic side effects.Through a large amount of it was verified that with modern The active constituent of technology, the natural active matter obtained from natural products can treat lung cancer, while the poison for mitigating chemicotherapy is secondary Effect.Therefore, it finds and effectively improves therapeutic efficiency, the small natural drug of toxic side effect is come to treat lung cancer be very necessary.
LibDock is one of interconnection method in Discovery Studio.The interconnection method first can for by Hot-zone figure is calculated in body active site, which includes polarity and nonpolar moiety;Then the ligand molecular of tripe systems elephant It is rigidly overlapped respectively to hot-zone figure and forms proper interaction;Then it carries out energy-optimised;Finally retain marking Higher docking conformation.
Summary of the invention
The present invention is directed to the above-mentioned prior art, and the present invention provides N6- Benzyladenosine (BAR) is thin in human lung cancer A kind of mechanism of apoptosis-promoting effect in born of the same parents' strain A549.
Technical solution of the present invention:
A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity, steps are as follows:
(1) cell culture: human lung carcinoma cell line A549 is suspended in the sterile DMEM culture solution containing inactivated serum, Being placed in concentration is 5%CO2, relative humidity 90%, cultivate in the incubator that temperature is 37 DEG C, to the adherent length of cell to culture bottle 70%~80% passage of floor space 1 time;
(2) drug is prepared: BAR 0.1%DMSO dissolution respectively continues the oTR that will have been dissolved with sterile DMEM media Being diluted to concentration is 0.1 μM -30 μM, filtration sterilization, room temperature preservation;
(3) it handles cell: the cell for being in logarithmic growth phase in step (1) is digested with pancreatin, it is dilute after cell count It releases, diluting cells density is 3 × 104~5 × 104A/ml, piping and druming mix, and by cell inoculation in 96 orifice plates, every hole takes 100 μ l After human lung carcinoma cell line A549,12h, after cell is adherent, 7 groups of experiments of setting, every group of 4 multiple holes, the 1st group: blank control group; 2nd group: 100 μ Μ BAR group;3rd group: 20 μM BAR group;4th group: 10 μ Μ BAR group;5th group: 2 μ Μ BAR group;6th group: 1 μ Μ BAR group;7th group: 0.2 μ Μ BAR group;The corresponding drug of 10 μ l is added into each group respectively, after mixing gently, is placed in concentration For 5%CO2, relative humidity 90%, be incubated for 2 days in the incubator that temperature is 37 DEG C, detection cell inhibitory effect activity;
(4) influence of the bioinformatics detection BAR to archaeal dna polymerase: firstly, being found used in us in PDB lane database Archaeal dna polymerase, setting parameter the structure of archaeal dna polymerase is optimized;Then look for the active site of archaeal dna polymerase;It is quasi- Standby BAR structural formula simultaneously optimizes;The method of LibDock carries out molecular docking, can successively check the docking structure of each ligand, It is ranked up according to scoring functions.
Beneficial effects of the present invention: data of the invention, which are established, may interfere with DNA polymerization in tumour cell in the basic element of cell division Enzymes biocatalysis synthetic DNA is to inhibit on the survival of tumour cell and the basis of proliferation.
Detailed description of the invention
Fig. 1 is inhibited proliferation of the BAR to A549.
Specific embodiment
Below in conjunction with attached drawing and technical solution, a specific embodiment of the invention is further illustrated.
Cell, kit and the reagent that the present invention uses: A549 cell, fetal calf serum, dual anti-(penicillin/strepto- Element), DMEM culture medium, BAR.
Embodiment 1
BAR inhibits A549 cell Proliferation: the cell in logarithmic growth phase digested with pancreatin, after cell count, and dilution, Diluting cells density is 3 × 104~5 × 104A/ml, piping and druming mix, and by cell inoculation in 96 orifice plates, every hole takes 100 μ l people After 12h, after cell is adherent, 7 groups of experiments are arranged in lung cancer cell types, every group of 4 multiple holes, and the 1st group: blank control group;The 2 groups: 100 μM of BAR groups;3rd group: 20 μM BAR group;4th group: 10 μM BAR group;5th group: 2 μ Μ BAR group;6th group: 1 μ Μ BAR group;7th group: 0.2 μ Μ BAR group;The corresponding drug of 10 μ l is added into each group respectively, after mixing gently, being placed in concentration is 5%CO2, relative humidity 90%, be incubated for 2 days in the incubator that temperature is 37 DEG C, detect the cell in 96 orifice plates with CCK-8 method Light absorption value, BAR significantly inhibits the proliferation of A549 as the result is shown, wherein IC50=1.21 μM.
Embodiment 2
Bioinformatics detects influence of the BAR to archaeal dna polymerase: firstly, finding used in us in PDB lane database Archaeal dna polymerase, setting parameter optimize the structure of archaeal dna polymerase;Then look for the active site of archaeal dna polymerase;Prepare BAR structural formula simultaneously optimizes;The method of LibDock carries out molecular docking, can successively check the docking structure of each ligand, press It is ranked up according to scoring functions.It is simulated and is found by bioinformatics molecular docking, BAR and archaeal dna polymerase are subjected to molecule mould Quasi- docking, BAR can be very good to be entrenched in the active pocket of archaeal dna polymerase crystal model, small molecule compatibility scoring functions Libdockscore value is analysis shows BAR can inhibit the activity of archaeal dna polymerase multiple to influence DNA in conjunction with archaeal dna polymerase Process processed inhibits cell Proliferation.

Claims (1)

1. a kind of basic element of cell division is by inhibiting DNA polymerase activity to inhibit the method for cell Proliferation, which is characterized in that step is such as Under:
(1) cell culture: human lung carcinoma cell line A549 is suspended in the sterile DMEM culture solution containing inactivated serum, is placed in Concentration is 5%CO2, relative humidity 90%, cultivate in the incubator that temperature is 37 DEG C, to the adherent length of cell to culture bottle bottom surface 70%~80% long-pending passage 1 time;
(2) drug is prepared: BAR 0.1%DMSO dissolution respectively continues to be diluted the oTR dissolved with sterile DMEM media It is 0.1 μM -30 μM to concentration, filtration sterilization, room temperature preservation;
(3) it handles cell: the cell for being in logarithmic growth phase in step (1) is digested with pancreatin, after cell count, dilution is dilute Releasing cell density is 3 × 104~5 × 104A/ml, piping and druming mix, and by cell inoculation in 96 orifice plates, every hole takes 100 μ l people's lungs After cancer cell line A549,12h, after cell is adherent, 7 groups of experiments of setting, every group of 4 multiple holes, the 1st group: blank control group;2nd Group: 100 μ Μ BAR groups;3rd group: 20 μM BAR group;4th group: 10 μ Μ BAR group;5th group: 2 μ Μ BAR group;6th group: 1 μ Μ BAR group;7th group: 0.2 μ Μ BAR group;The corresponding drug of 10 μ l is added into each group respectively, after mixing gently, being placed in concentration is 5%CO2, relative humidity 90%, be incubated for 2 days in the incubator that temperature is 37 DEG C, detection cell inhibitory effect activity;
(4) influence of the bioinformatics detection BAR to archaeal dna polymerase: firstly, finding the DNA used in us in PDB lane database Polymerase, setting parameter optimize the structure of archaeal dna polymerase;Then look for the active site of archaeal dna polymerase;Prepare BAR Structural formula simultaneously optimizes;The method of LibDock carries out molecular docking, can successively check the docking structure of each ligand, according to Scoring functions are ranked up.
CN201811213728.7A 2018-10-18 2018-10-18 A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity Withdrawn CN109385459A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811213728.7A CN109385459A (en) 2018-10-18 2018-10-18 A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811213728.7A CN109385459A (en) 2018-10-18 2018-10-18 A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity

Publications (1)

Publication Number Publication Date
CN109385459A true CN109385459A (en) 2019-02-26

Family

ID=65427484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811213728.7A Withdrawn CN109385459A (en) 2018-10-18 2018-10-18 A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity

Country Status (1)

Country Link
CN (1) CN109385459A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236216A1 (en) * 2001-06-12 2003-12-25 Devos Rene Robert 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication
TW201124141A (en) * 2011-04-09 2011-07-16 Medivir Ab HCV nucleoside inhibitor
CN103635576A (en) * 2011-06-30 2014-03-12 箭头研究公司 Compositions and methods for inhibiting gene expression of Hepatitis B Virus
CN107142298A (en) * 2017-06-15 2017-09-08 大连理工大学 A kind of applications of cell-cycle arrest agent 6BAR in human lung carcinoma cell
CN107326010A (en) * 2017-06-15 2017-11-07 大连理工大学 A kind of applications of cell-cycle arrest agent 6BAR in human breast cancer cell

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236216A1 (en) * 2001-06-12 2003-12-25 Devos Rene Robert 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN1516590A (en) * 2001-06-12 2004-07-28 - 4'-substituted nucleosides
TW201124141A (en) * 2011-04-09 2011-07-16 Medivir Ab HCV nucleoside inhibitor
CN103635576A (en) * 2011-06-30 2014-03-12 箭头研究公司 Compositions and methods for inhibiting gene expression of Hepatitis B Virus
CN107142298A (en) * 2017-06-15 2017-09-08 大连理工大学 A kind of applications of cell-cycle arrest agent 6BAR in human lung carcinoma cell
CN107326010A (en) * 2017-06-15 2017-11-07 大连理工大学 A kind of applications of cell-cycle arrest agent 6BAR in human breast cancer cell

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SARA CASTIGLIONI等: "N6-Isopentenyladenosine and its analogue N6-Benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells", 《ANTI-CANCER AGENTS MEDICINAL CHEMISTRY》 *
周仲楼等: "腺苷对人肺腺癌细胞A549增殖和细胞周期的影响", 《温州医学院学报》 *
李燕: "《精编分子生物学实验技术》", 30 September 2017, 世界图书出版公司 *
魏来: "《肝脏疾病》", 31 July 2006, 中国医药科技出版社 *

Similar Documents

Publication Publication Date Title
Vesela et al. Common chemical inductors of replication stress: focus on cell-based studies
Hou et al. Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds
CN106177961B (en) The application of VCP inhibitor and oncolytic virus in antineoplastic is prepared
CN101478978B (en) Delta-tocotrienol treatment and prevention of pancreatic cancer
CN108913662B (en) A kind of method of the functional high-throughput medication screening of lung cancer
Zapevalova et al. Synthesis, molecular docking, in vitro and in vivo studies of novel dimorpholinoquinazoline-based potential inhibitors of PI3K/Akt/mTOR Pathway
JP5696191B2 (en) Anticancer stem cell agent
CN105886507B (en) Application of the long-chain non-coding RNA FAM83H-AS1 in preparation treatment non-small cell lung cancer drug
CN109385459A (en) A kind of method that basic element of cell division inhibits cell Proliferation by inhibition DNA polymerase activity
CN107903210B (en) Small molecule inhibitor SLD4650 and application thereof in pharmacy
Olmo et al. In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells
CN106727620A (en) Application of the phosphopyridoxal pyridoxal phosphate in the medicine for preparing treatment oophoroma
Singh et al. Developmental Genotoxicology and genotoxicity testing guidelines: an overview on erythromycin genotoxicity
CN107142298A (en) A kind of applications of cell-cycle arrest agent 6BAR in human lung carcinoma cell
CN106727560A (en) A kind of application of Comptothecin compounds as topoisomerase enzyme inhibitor in chronic hepatic diseases medicine is treated
Rao et al. Carcinogenicity of nicotine and signal pathways in cancer progression: a review
CN107375292A (en) A kind of new application of Triazolopyridazine compound
CN106512022A (en) Application of hydroxysafflor yellow A-red blood cell adhesion chondroitin sulfate A receptor protein polypeptide compound to preparing of antitumor drug
CN108164529B (en) Small molecule inhibitor SLD9059 and application thereof in pharmacy
CN112546066A (en) Anticancer composition, combination product, preparation method and application thereof
CN105274152A (en) Curcumin biotransformation method, products of curcumin biotransformation method and application of products of curcumin biotransformation method
CN104961752A (en) Binuclear copper (II) and zoledronic acid coordination complex and application thereof
CN104758286A (en) Applications of 1-benzyl-4-(2,4-dichloro phenethylamino)piperidine in preparation of antitumor medicines
CN109260194A (en) Praeruptorin A is alleviating the application in anti-tumor drug Nephrotoxicity Caused By Cisplatin
CN109771428A (en) Celastrol combines application of the erastin in the drug for the treatment of non-small cell lung cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20190226

WW01 Invention patent application withdrawn after publication